



ECNP Association

Annual Report 2025

VERENIGING ECNP Association (ECNP)

Annual Report 2025

1. About ECNP	3
Objectives	3
Executive Committee	4
2. Activities 2025	7
Promoting and disseminating science	7
Fostering talent	8
Public outreach	8
3. Financial Overview	9
Financial statements	9
4. Future Outlook	11



Vereniging ECNP Association is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

1. About ECNP

ECNP is an independent European scientific association dedicated to ensuring that advances in the understanding of brain function and human behaviour are translated into better treatments and enhanced public health.

The mission of ECNP is to advance the science of the brain, promote better treatment and enhance brain health. It is non-profit-making.

Address:	Daltonlaan 400, 3584 BK Utrecht
E-mail:	secretariat@ecnp.eu
Website:	https://www.ecnp.eu
RSIN:	866180813
Dutch Chamber of Commerce:	92812538
Dutch TAX number:	NL866180813B01
ANBI:	Vereniging ECNP Association is a public-interest-serving entity (<i>algemeen nut beogende instelling</i> – ANBI) under Dutch tax law.

ECNP Association is also referred to as the 'European College of Neuropsychopharmacology' or as 'ECNP'.

Objectives

ECNP was founded to stimulate high-quality experimental and clinical research in applied and translational neuroscience, with a view to advancing the development of better treatments for those suffering from disorders of the brain.

ECNP seeks to bring together all those involved in or interested in the scientific study of applied and translational neuroscience by arranging scientific meetings, educational activities, research networks, and publishing and disseminating scientific research; to offer guidance and information to the scientific community and other relevant stakeholders on matters pertaining to applied and translational neuroscience; and to provide a format for coordination and for development of common standards in Europe.

Executive Committee

Up to 13 October 2025

Officers

Martien Kas
President
University of Groningen
The Netherlands

Andreas Reif
President-Elect
University Hospital Frankfurt
Germany

Elisabeth Binder
Vice-President
Max Planck Institute of Psychiatry
Munich, Germany

Suzanne Dickson
Secretary
University of Gothenburg
Sweden

Gitte Moos Knudsen
Past-President
Copenhagen University Hospital
Denmark

Brenda Penninx
Treasurer
Amsterdam University Medical Center
The Netherlands

Councillors

David Baldwin
University of Southampton
United Kingdom

Iiris Hovatta
University of Helsinki
Finland

Paolo Brambilla
University of Milan
Italy

Marin Jukić
University of Belgrade
Serbia

Iria Grande
Hospital Clinic de Barcelona
Spain

Marion Leboyer
University of Paris Est Créteil
France

Expert

Gerry-Dawson
P1vital, Ltd
Wallingford, United Kingdom

Ex officio members

John Cryan
Chair, Scientific Programme Committee
35th, 36th, 37th ECNP Congress
University College Cork
Ireland

Eduard Vieta
Editor-in-Chief, European
Neuropsychopharmacology
University of Barcelona
Spain

Andreas Meyer-Lindenberg
Editor-in-Chief, Neuroscience Applied
Central Institute of Mental Health (ZI)
Mannheim, Germany

Executive Director

Alexander Schubert

From 13 October 2025

Officers

Andreas Reif
President
University Hospital Frankfurt
Germany

Brenda Penninx
President-Elect
Amsterdam University Medical Center
The Netherlands

David Baldwin
Vice-President
University of Southampton
United Kingdom

Marion Leboyer
Secretary
University of Paris Est Créteil
France

Martien Kas
Past-President
University of Groningen
The Netherlands

John Cryan
Treasurer
University College Cork
Ireland

Councillors

Livia De Picker
University Psychiatric Hospital Duffel
Belgium

Marin Jukić
University of Belgrade
Serbia

Christina Dalla
University of Athens
Greece

Carmen Moreno
Hospital General
Universitario Gregorio Marañón
Spain

Vibe Gedsø Frøkjær
Rigshospitalet
Denmark

Experts

Gerry-Dawson
P1vital, Ltd
Wallingford, United Kingdom

James Rowe
University of Cambridge
United Kingdom

Suzanne Dickson
University of Gothenburg
Sweden

Ex officio members

Barbara Franke
Chair, Scientific Programme Committee
38th, 39th, 40th ECNP Congress
Radboud University Nijmegen
The Netherlands

Eduard Vieta
Editor-in-Chief,
European Neuropsychopharmacology
University of Barcelona
Spain

Andreas Meyer-Lindenberg
Editor-in-Chief, Neuroscience Applied
Central Institute of Mental Health (ZI)
Mannheim, Germany

Executive Director

Alexander Schubert

The members of the Executive Committee receive no remuneration for their role. The President receives € 15,000 per annum, payable to his institution, for secretarial assistance. Each Officer receives € 4,000 per annum, payable to his or her institution, for secretarial assistance. And each member of the Executive Committee is entitled to € 1,500 per annum to cover associated meeting costs, including ground transportation, lunch, dinner, drinks, etc.

2. ECNP Activities 2025

To execute its mission to support European applied and translational neuroscience, ECNP performs a number of activities annually, focusing especially on stimulating research, sponsoring education and raising awareness.

Promoting and disseminating science

European Neuropsychopharmacology

ECNP publishes, in partnership with Elsevier B.V., the international peer-reviewed journal *European Neuropsychopharmacology*, featuring the latest in applied brain science across the spectrum of basic and clinical and research.

The 2025 impact factor is 8.100.

ECNP Networks and Thematic Working Groups (TWGs)

These virtual, multi-centre European research clusters provide a unique platform for the collection and aggregation of continent-wide clinical data, in order to foster research collaboration and ideas-sharing across the translational neurosciences.

The 26 Networks and Thematic Working Groups collectively comprise one of ECNP's most far-reaching initiatives, bringing together several hundred of Europe's leading researchers in applied and translational neuroscience, and providing the springboard for some of the region's largest and most important projects in brain research.

The International Society for CNS Clinical Trials and Methodology (ISCTM)

ISCTM is an independent organisation devoted to advancing clinical research methods related to the development and use of central nervous system (CNS) therapeutics. Every two years the ECNP-ISCTM joint meeting brings together international stakeholders in academia, industry, government, and the regulatory and payer communities to address strategic clinical, regulatory, methodological and policy challenges in CNS clinical research. The joint meeting was held on 10-11 October 2025 in Amsterdam, the Netherlands.

ECNP Neuropsychopharmacology Award

This award, conferred annually, recognises exceptional research achievements in applied and translational neuroscience, alternating between basic and clinical science. The award comes with a prize of € 10,000, contingent upon publication of a review paper in *European Neuropsychopharmacology* within two years.

Winner 2025: Carmen Sandi, Switzerland (preclinical)

Carmen Sandi delivered her award lecture, 'Mitochondria in brain function and mental health', on 13 October 2025 at the 38th ECNP Congress in Amsterdam.

ECNP Citation Prize

Awarded to the most-cited research paper in the ECNP journal, *European Neuropsychopharmacology* (ENP) in the preceding two years, the award recognises and encourages impactful original research. Promoted by ECNP.

Winner 2025: Anita Sathyanarayanan et al., 'Multi-omics data integration methods and their applications in psychiatric disorders', *Eur. Neuropsychopharmacol*, 69 (2023) 26-46.

Fostering talent

ECNP Rising Star Award

The ECNP Rising Star Award honours early career researchers in applied and translational neuroscience who have the potential to advance the science of treatment and prevention of brain disorders. Conferred for the first time in 2020, in 2021 the number of awards was doubled. The award comes with an unrestricted prize of € 2,000.

Winner 2025: Susanne Meinert, Germany

Susanne Meinert's award presentation, 'Mind and matter: how depression reshapes the brain', was delivered on 13 October 2025 at the 38th ECNP Congress in Amsterdam.

ECNP Research Internship

The ECNP Research Internship (ERI) offers 15 early career scientists the opportunity of a short two-week exploratory experience in another European country.

Public outreach

European Affairs

ECNP collaborates with a number of European societies to build European research and clinical capacity and advance the interests of the neuroscience research and best-practices treatment in Europe.

- ALBA Network for diversity, equity and inclusion in neuroscience – supporter
- Biomedical Alliance in Europe – member
- European Brain Council (EBC) – founding member
- European Federation of Psychiatric Trainees (EFPT) – supporter
- Federation of European Neuroscience Societies (FENS) – founding member
- Global Alliance of Mental Illness Advocacy Networks (GAMIAN-Europe) – member

3. Financial Overview

ECNP’s funding derives from donations, journal royalties, membership dues, and investment income.

Its policy at all times to handle its disposable assets in a responsible and sustainable manner according to the following principles:

- Proactive tax and regulatory compliance
- Capital preservation, adhering to agreed levels
- Budgetary discipline
- Ongoing diversification of the revenue base

To give substance to this, ECNP invests in securities through an established asset manager according to a defensive mandate. Its goal is to preserve wealth and ensure the Association can deliver its public-good activities, not to maximise return or to increase its capital base.

Financial statements 2025

Balance sheet as at 31 December 2025

(after appropriation of profit/losses)

	31 December 2025		31 December 2024	
	€	€	€	€
ASSETS				
<u>FIXED ASSETS</u>				
<u>Financial fixed assets</u>				
Securities		14,848,472		14,848,472
<u>CURRENT ASSETS</u>				
<u>Receivables, prepayments and accrued income</u>				
Debtors	28,726		20,000	
Taxes	5,103		16,445	
Other receivables	70,837		145,013	
		104,666		181,458
<u>Bank deposits</u>		499,271		1,046,048
		<u>15,452,409</u>		<u>16,075,978</u>

		31 December 2025		31 December 2024	
		€	€	€	€
EQUITY AND LIABILITIES					
<u>EQUITY AND FUNDS</u>	(4)				
Other reserves			15,257,967		15,930,613
<u>CURRENT LIABILITIES</u>	(5)				
Trade creditors		65,786		34,870	
Other liabilities		128,656		110,495	
			194,442		145,365
			<u>15,452,409</u>		<u>16,075,978</u>

Statement of income and expenditure 2025

	2025	2024
	€	€
Income		
Membership fees	140,047	6,651
Royalties	70,018	0
Other income	0	1,000,000
Interest and similar income	12,043	857
<u>SUM OF INCOME</u>	<u>222,108</u>	<u>1,007,508</u>
Expenses		
<u>MANAGEMENT AND ADMINISTRATION</u>		
Administration	395,728	0
Other expenses	499,026	7,256
<u>SUM OF EXPENSES</u>	<u>894,754</u>	<u>7,256</u>
<u>RESULT</u>	<u>(672,646)</u>	<u>1,000,252</u>

4. Future Outlook

As ECNP heads towards its fourth decade, the ECNP entities continue to develop and refine their purpose and strategy to determine where the most impactful contributions can be made and how relevance and long-term (economic) viability can be assured. Questions under review include:

- How the landscape of European brain science is changing and how ECNP's programmes and activities should adapt to these changes.
- How technology is reshaping the ways in which science is generated, disseminated and consumed, and how ECNP should respond.
- How the organisation's activities can meet the scale of the need they are designed to serve and achieve an impact commensurate with the organisation's mission.
- How the organisation can fulfil its social obligation to reduce its carbon footprint and contribute to environmental preservation.

The result of this process is an ongoing recalibration of the entities' portfolios both to optimise the quality and reach of their current activities and to increase their impact on the issues that shape the future of the field.

Promoting and disseminating science

The ECNP Networks programme, already one of the most productive collaborative platforms of its type in European applied neuroscience, will be expanded to include up to 30 thematic Networks, with ongoing refinement of the portfolio to ensure maximum topical coverage and research effectiveness.

The ECNP Roadmap for Precision Psychiatry will be broadened from its annual meeting to include ECNP-led research projects to advance precision psychiatry models and accelerate biomarker research.

Fostering talent


ECNP and its allied entities will continue to develop their educational offerings, leveraging in particular online delivery to reach the largest numbers of users with the highest-quality and most impactful content at the lowest cost and smallest environmental footprint.

A professional career development trajectory from Early Career Scientist to Fellow Member will be built to ensure that members of the ECNP community at all stages of their career are able to engage and benefit.

The ECNP Early Career Academy of exceptional early career scientists in Europe will be expanded with an additional 20 members, with a view bringing its total membership up to 100.

Public outreach

ECNP will address the pressing issue of European medicines innovation and the availability of the latest psychiatric treatments for European patients with an awareness-raising campaign to advocate for more patient-oriented policies and parity between mental illness and other disease areas.



© 2026 European College of Neuropsychopharmacology